An agonistic TrKb mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 9, 2010, Pages 4722-4731

  Bai, Yujing ^a,b   Xu, Jing ^c   Brahimi, Fouad ^a   Zhuo, Yehong ^b   Sarunic, Marinko V ^c   Uri Saragovi, H ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b SUN YAT SEN UNIVERSITY   (China)

^c SIMON FRASER UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRKB; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME SPECIFICITY; FOURIER ANALYSIS; GLAUCOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER TRANSECTION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE STUDY; RAT; RETINA GANGLION CELL; RETINA INJURY; WESTERN BLOTTING; ACUTE DISEASE; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CELL LINE; CHRONIC DISEASE; CYTOLOGY; DISEASE MODEL; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY; METABOLISM; METHODOLOGY; MOUSE; OPTIC NERVE DISEASE; PATHOLOGY; WISTAR RAT;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; AXOTOMY; CELL LINE; CELL SURVIVAL; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GLAUCOMA; HUMANS; IMMUNOTHERAPY; KIDNEY; MICE; MICE, INBRED BALB C; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; RATS; RATS, WISTAR; RECEPTOR, TRKB; RETINAL GANGLION CELLS;

EID: 77955361230     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-5032     Document Type: Article

References (53)

1. Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron. 2002; 33: 9-12.
2. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000; 41: 764-774.
3. Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A. Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Mol Cell Neurosci. 2009; 40: 410-420.
4. Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol. 2004; 58: 341-354.
5. Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Dev Neurobiol. 2007; 67: 884-894.
6. Rudzinski M, Saragovi HU. Glaucoma: validated and facile in vivo experimental models of a chronic neurodegenerative disease for drug development. Curr Med Chem. 2005; 5: 43-49.
7. Shi Z, Rudzinski M, Meerovitch K, et al. α2-Macroglobulin is a mediator of retinal ganglion cell death in glaucoma. J Biol Chem. 2008; 283: 29156-29165.
8. Cheng L, Sapieha P, Kittlerova P, Hauswirth WW, Di Polo A. TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci. 2002; 22: 3977-3986.
9. Pernet V, Di Polo A. Synergistic action of brain-derived neurotrophic factor and lens injury promotes retinal ganglion cell survival, but leads to optic nerve dystrophy in vivo. Brain. 2006; 129: 1014-1026.
10. Peinado-Ramon P, Salvador M, Villegas-Perez MP, Vidal-Sanz M. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells: a quantitative in vivo study. Invest Ophthalmol Vis Sci. 1996; 37: 489-500.
11. Ko ML, Hu DN, Ritch R, Sharma SC. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000; 41: 2967-2971.
12. Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brainderived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003; 44: 4357-4365.
13. Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000; 41: 3460-3466.
14. Segal RA. Selectivity in neurotrophin signaling: theme and variations. Annu Rev Neurosci. 2003; 26: 299-330.
15. Fu QL, Li X, Yip HK, et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience. 2009; 162: 375-382.
16. Maliartchouk S, Feng Y, Ivanisevic L, et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol. 2000; 57: 385-391.
17. Bruno MA, Clarke PB, Seltzer A, et al. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci. 2004; 24: 8009-8018.
18. Saragovi HU, Zheng W, Maliartchouk S, et al. A TrkA-selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals. J Biol Chem. 1998; 273: 34933-34940.
19. Srinivasan B, Roque CH, Hempstead BL, Al-Ubaidi MR, Roque RS. Microglia-derived pronerve growth factor promotes photoreceptor cell death via p75 neurotrophin receptor. J Biol Chem. 2004; 279: 41839-41845.
20. Lebrun-Julien F, Duplan L, Pernet V, et al. Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomous mechanism. J Neurosci. 2009; 29: 5536-5545.
21. Xu J, Molday LL, Molday RS, Sarunic MV. In vivo imaging of the mouse model of X-linked juvenile retinoschisis with Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2009; 50: 2989-2993.
22. LeSauteur L, Maliartchouk S, Le Jeune H, Quirion R, Saragovi HU. Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. J Neurosci. 1996; 16: 1308-1316.
23. Guillemard V, Ivanisevic L, Garcia AG, et al. An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot, and interactions with p75 co-receptors. Dev Neurobiol. 2010; 70: 150-164.
24. Zaccaro MC, Ivanisevic L, Perez P, Meakin SO, Saragovi HU. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. J Biol Chem. 2001; 276: 31023-31029.
25. Yan C, Liang Y, Nylander KD, et al. p75 nerve growth factor as an antiapoptotic complex: independence versus cooperativity in protection from enediyne chemotherapeutic agents. Mol Pharmacol. 2002; 61: 710-719.
26. Maliartchouk S, Debeir T, Beglova N, Cuello AC, Gehring K, Saragovi HU. Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. J Biol Chem. 2000; 275: 9946-9956.
27. Atwal JK, Massie B, Miller FD, Kaplan DR. The TrkB-Shc site signals neuronal survival and local axon growth via MEK and P13-kinase. Neuron. 2000; 27: 265-277.
28. Urcola JH, Hernandez M, Vecino E. Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp Eye Res. 2006; 83: 429-437.
29. Buckingham BP, Inman DM, Lambert W, et al. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci. 2008; 28: 2735-2744.
30. Danias J, Kontiola AI, Filippopoulos T, Mittag T. Method for the noninvasive measurement of intraocular pressure in mice. Invest Ophthalmol Vis Sci. 2003; 44: 1138-1141.
31. Perez P, Coll PM, Hempstead BL, Martin-Zanca D, Chao MV. NGF binding to the Trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains. Mol Cell Neurosci. 1995; 6: 97-105.
32. Watson F, Porcionatto M, Bhattacharyya A, Stiles C, Segal R. TrkA glycosylation regulates receptor localization and activity. J Neurobiol. 1999; 39: 323-336.
33. Saragovi HU, Zaccaro MC. Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites. Curr Pharm Des. 2002; 8: 2201-2216.
34. Zaccaro MC, Lee HB, Pattarawarapan M, et al. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem Biol 2005; 12: 1015-1028.
35. Qian MD, Zhang J, Tan XY, Wood A, Gill D, Cho S. Novel agonist monoclonal antibodies activate TrkB receptors and demonstrate potent neurotrophic activities. J Neurosci. 2006; 26: 9394-9403.
36. Hu Y, Cho S, Goldberg J. Neurotrophic effect of a novel TrkB agonist on retinal ganglion cells. Invest Ophthalmol Vis Sci. 2010; 51: 1747-1754.
37. Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma, III: quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982; 100: 135-146.
38. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114: 205-209.
39. Suzuki Y, Iwase A, Araie M, et al. Risk factors for open-angle glaucoma in a Japanese population: the Tajimi study. Ophthalmology. 2006; 113: 1613-1617.
40. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nature Rev. 2009; 5: 311-322.
41. Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci. 2000; 21: 93-98.
42. Pease ME, Zack DJ, Berlinicke C, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009; 50: 2194-2200.
43. Zhi Y, Lu Q, Zhang CW, Yip HK, So KF, Cui Q. Different optic nerve injury sites result in different responses of retinal ganglion cells to brain-derived neurotrophic factor but not neurotrophin-4/5. Brain Res. 2005; 1047: 224-232.
44. Rohrer B, LaVail MM, Jones KR, Reichardt LF. Neurotrophin receptor TrkB activation is not required for the postnatal survival of retinal ganglion cells in vivo. Exp Neurol. 2001; 172: 81-91.
45. Neet KE, Campenot RB. Receptor binding, internalization, and retrograde transport of neurotrophic factors. Cell Mol Life Sci. 2001; 58: 1021-1035.
46. Zhang Y, Moheban DB, Conway BR, Bhattacharyya A, Segal RA. Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation. J Neurosci. 2000; 20: 5671-5678.
47. Grimes ML, Zhou J, Beattie EC, et al. Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. J Neurosci. 1996; 16: 7950-7964.
48. MacInnic BL, Campenot RB. Retrograde support of neuronal survival without retrograde transport of nerve growth factor. Science. 2002; 295: 1536-1539.
49. Ye H, Kuruvilla R, Zweifel LS, Ginty DD. Evidence in support of signaling endosome-based retrograde survival of sympathetic neurons. Neuron. 2003; 39: 57-68.
50. Pasutto F, Matsumoto T, Mardin CY, et al. Heterozygous NTF4 mutations impairing neurotrophin-4 signaling in patients with primary open-angle glaucoma. Am J Hum Genet. 2009; 85: 447-456.
51. Srinivasan VJ, Ko TH, Wojtkowski M, et al. Noninvasive volumetric imaging and morphometry of the rodent retina with high-speed, ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci. 2006; 47: 5522-5528.
52. Ruggeri M, Wehbe H, Jiao S, et al. In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2007; 48: 1808-1814.
53. Kim KH, Puoris'haag M, Maguluri GN, et al. Monitoring mouse retinal degeneration with high-resolution spectral-domain optical coherence tomography. J Vis. 2008; 8: 17: 1-11.